A recent poll conducted by Pharmacy Business reveals significant division across the community pharmacy sector regarding operational readiness for the newly launched NHS Meningococcal B (MenB) student vaccination service.
When asked how prepared their teams were to deliver the advanced service, only 26% of respondents stated they were "fully prepared and ready."
The majority expressed reservations, with 30% noting they were "ready, but workload is high" and another 30% admitting they remained "unsure" about their participation or operational setup.
Meanwhile, 13% confirmed they were "not participating" in the national rollout entirely.
The survey findings reflect broader sector concerns surrounding capacity constraints, administrative demands, and supply chain logistics ahead of the autumn university term.
Commissioned as a time-limited Advanced Service running from 20 July 2026 through March 2027, the MenB vaccination drive targets incoming higher education students and Year 13 school leavers following localized outbreaks earlier in the year.
The initiative aims to vaccinate roughly one million eligible young adults before they move into shared student accommodation.
While representative bodies such as Community Pharmacy England (CPE) welcomed the sector’s inclusion in the national campaign, responses to the Pharmacy Business poll underscore the ongoing pressure on front-line teams.
Stock allocation processes and mandatory requirements to list open booking slots through the National Booking Service (NBS) have added to initial friction for independent contractors.
Under the terms of the service specification, participating pharmacies receive an Item of Service fee of £10.06 per dose administered, alongside potential one-off mobilization payments.
However, with the 13% opting out, financial incentives appears insufficient to offset current staffing challenges and operational hurdles.
As first-dose appointments progress through the summer months, industry leaders continue to urge NHS England and commissioners to ensure smooth vaccine supply flows and IT platform support so community pharmacies can effectively deliver protection against invasive meningococcal disease without overstretching primary care teams.
